Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with No Late Stent Thrombosis or Additional Major Adverse Cardiac Events Out to Three Years

BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac Events (MACE), and no late stent thrombosis in patients treated with either Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System or its MULTI-LINK VISION(R) metallic coronary stent. Additionally, data presented from a meta- (combined) analysis of SPIRIT II and SPIRIT III trials at nine months reaffirmed the superiority of Abbott's XIENCE V compared to the TAXUS(R) paclitaxel-eluting coronary stent system in a variety of measures.

These data were presented today at the EuroPCR meeting in Barcelona.

"The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and ARC definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigator in the SPIRIT trials. "In addition, a meta-analysis of the SPIRIT II and III data again demonstrated the superiority of the XIENCE V system to the TAXUS system in important measures that matter to patients including renarrowing of a treated vessel and major adverse cardiac events."

A meta-analysis of approximately 1,300 patients from the SPIRIT II and SPIRIT III clinical trials conducted by the Cardiovascular Research Foundation indicated that the XIENCE V system demonstrated superiority over the TAXUS stent in angiographic (imaging) and clinical endpoints, with an excellent safety profile.

Specifically, data from the meta-analysis demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System was superior to the TAXUS stent in:

    -- Reducing the occurrence of major 
'"/>




Page: 1 2 3 4 

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results
in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the
Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and
Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to
Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the

American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:6/19/2013)...  Haemonetics Corporation (NYSE: HAE ) ... of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation (NASDAQ: ... medical devices currently manufactured in Braintree ... of integrated manufacturing solutions, components, products and repair, ...
(Date:6/19/2013)... Dr. Davis Lee , CMIO for PIH Health ... 2013 AMDIS Award, a prestigious recognition saluting excellence and ... "On behalf of Allscripts, I,d like to congratulate Dr. ... efforts to improve patient care and population health," said ... Officer of Allscripts. "We are committed to our partnership ...
(Date:6/19/2013)... , June 19, 2013 The American Association ... from Maryland , announced today the filing ... Washington, D.C. , asking that the scheduled ... for durable medical equipment (DME) be stopped because of serious ... Health and Human Services (HHS) Secretary Kathleen Sebelius ...
Breaking Medicine Technology:Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5
... After Ozarelix Was Maintained For ... Up To Six Months, ... Thereafter, IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ... Company,s drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the ...
... Hosts Key Investigator Meeting for European Participants in ... 3 AGENDA Trial Targeting Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that data from ... plus chemotherapy would be,presented at the opening session ...
Cached Medicine Technology:Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 2Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 3Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 4Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 5
(Date:6/19/2013)... 19, 2013 PrettySkin4Less announces it is ... serums by top skin care manufacturer EMINENCE to ... of vitamins, minerals and active organic ingredients to promote ... many other beauty products offer. For this reason it’s ... , "I like products that do what they ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... As Januvia lawsuit ... in courts throughout the U.S., Bernstein Liebhard LLP notes ... held a meeting to discuss the safety of Januvia ... According to a June 12th report from Bloomberg.com, the ... Januvia and similar drugs, following a recent study that ...
(Date:6/19/2013)... is believed to be the largest follow-up record of ... a movement disorder that can cause crippling muscle ... success rates and lasting benefits. , Michele Tagliati, MD, ... Medical Center,s Department of Neurology, and Ron L. Alterman, ... Israel Deaconess Medical Center in Boston, published the study ...
(Date:6/19/2013)... study reveals significant disparities between minority and white ... treatment programs. Moreover, these disparities vary widely from ... that for most states there,s something amiss," says ... biostatistics. "There are strong racial and ethnic disparities ... abuse treatment programs successfully, and those disparities are ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... PharmaTech (Cayman) Inc.,(NYSE: WX ), a leading ... with operations in China and the,United States, today announced ... WuXi PharmaTech Board of Directors. , ... Dr. Ge Li, WuXi,s Chairman and Chief ...
... Receptors and Cell Signaling at UH and MethodistHOUSTON, Feb. ... of a $5.5 million grant to the University ... (ETF). As a result of the ETF grant, UH ... to carry out laboratory research and to create next-generation ...
... today for the event to take place November 21-22 ... 5 The Leukemia & Lymphoma Society (LLS) and ... officials, announcement today granting the two organizations permission to ... November 21-22, 2009. The event, Women,s Running ...
... W.Va., Feb. 5 ReBuilder Medical Technologies, Inc. (Pink ... treatments for diabetic peripheral neuropathy and ... increase in sales for the month of January. (Logo: ... appear to be recession proof and this monthly sales ...
... unemployment rate facing Americans with disabilities , WASHINGTON, Feb. ... the first time, release employment and unemployment data on ... information will assist the nation in understanding how changing ... it is widely believed that this group typically faces ...
... February 5, 2009 Narcotics have an irreversible effect ... illness, according to Dr. Stphane Potvin of the Universit ... Louis-H Lafontaine Hospital. , According to his research, ... suffer from drug addiction. The study has shown that ...
Cached Medicine News:Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 2Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 2Health News:Internationally Acclaimed Researcher Joins UH Faculty 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 4Health News:Internationally Acclaimed Researcher Joins UH Faculty 5Health News:Internationally Acclaimed Researcher Joins UH Faculty 6Health News:The Leukemia & Lymphoma Society and Women's Running Magazine Join Forces to Launch New All-Women Half Marathon in St. Petersburg 2Health News:ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09 2Health News:U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6 2
... is an FDA approved rapid ... blood test used to aid ... infection. This CLIA waived test, ... antibodies to HIV-1, requires only ...
... The Acceava Mononucleosis test provides ... Mononucleosis with a simple procedure that ... Side-by-side evaluations with competitive products will ... These attributes enable you to deliver ...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
... Influenza A+B test allows for the ... A and type B antigens directly ... nasal aspirate specimens. The test is ... rapid differential diagnosis of acute influenza ...
Medicine Products: